Ads
related to: biological drugs for osteoarthritis pain symptoms arthritis
Search results
Results From The WOW.Com Content Network
TNF-α Inhibitors are the most commonly prescribed medication among biologic response modifiers used to treat arthritis. Patients with rheumatic conditions may have higher levels of TNF in the systemic circulation. [18] As a result of increased levels of TNF, there would be more inflammation and persistent symptoms of arthritis. [18]
A disease-modifying osteoarthritis drug (DMOAD) is a disease-modifying drug that would inhibit or even reverse the progression of osteoarthritis. [1] Since the main hallmark of osteoarthritis is cartilage loss, a typical DMOAD would prevent the loss of cartilage and potentially regenerate it.
In clinical studies, NGF inhibitors have demonstrated efficacy in reducing pain and improving function in persons with knee or hip osteoarthritis. [2] While injectable NGF inhibitors (anti-NGF antibodies) have demonstrated greater efficacy in pain relief compared to NSAID and opioid medications, [3] those receiving the treatment were more likely to experience rapid progression of the disease ...
Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name), the term has come to pertain to many other diseases, such as Crohn's disease, lupus erythematosus, Sjögren syndrome, immune thrombocytopenic purpura, myasthenia gravis, sarcoidosis, and various others.
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). [7] It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. [7]
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis Intetumumab [83] [84] mab: human: CD51: solid tumors (prostate cancer, melanoma) Inolimomab: mab: mouse: CD25 (α chain of IL-2 receptor) graft versus host disease: Inotuzumab ozogamicin [39] Besponsa: mab: humanized: CD22: Y: Acute ...